Back to Search Start Over

"In situ" endografting in the treatment of arterial and graft infections.

Authors :
Haidar GM
Hicks TD
Strosberg DS
El-Sayed HF
Davies MG
Source :
Journal of vascular surgery [J Vasc Surg] 2017 Jun; Vol. 65 (6), pp. 1824-1829. Date of Electronic Publication: 2017 Mar 27.
Publication Year :
2017

Abstract

Objective: Endografts (eg, aortic aneurysm device or covered stent) are increasingly being used to temporize or treat arterial and graft infections in inaccessible areas, in patients with compromised anatomy, or in the presence of active bleeding or rupture. This summary examines the evidence for "in situ" endografting in the treatment these conditions.<br />Methods: A two-level search strategy of the literature (MEDLINE, PubMed, Google Scholar, and The Cochrane Library) was performed for relevant articles listed between January 2000 and December 2015. The review was confined to patients with primary and secondary bacterial or viral arterial infections, with or without fistulization and infection of bypass grafts and arteriovenous accesses. For the purposes of this summary, endografts can be considered to be an aortic aneurysm device or a covered stent.<br />Results: There are no societal guidelines. Endografts have been successfully applied to mycotic arterial aneurysms, aortoenteric, aortobronchial, and arterioureteric fistulae, and to anastomotic bleeds secondary to infection. Multiple reports indicate success at the control of hemorrhage in all locations. Short-term outcomes are good, but fatal infection-related complications, especially if antibiotic therapy is halted, are well reported and necessitate a more definitive plan for the long term.<br />Conclusions: Stent grafts remain an important and viable option for the treatment of mycotic aneurysms, aortoesophageal and aortobronchial fistulae, and infected pseudoaneurysms in anatomically or technically inaccessible locations. In patients with a short life span (<6 months), no further intervention is generally required. In patients with a predicted life span >6 months, careful consideration should be given to a more definitive procedure. Life-long appropriate antibiotic therapy is strongly recommended for any patient receiving an endograft in an infected field.<br /> (Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-6809
Volume :
65
Issue :
6
Database :
MEDLINE
Journal :
Journal of vascular surgery
Publication Type :
Academic Journal
Accession number :
28359717
Full Text :
https://doi.org/10.1016/j.jvs.2016.12.134